KUNMING, China, March 31 /Xinhua-PRNewswire-FirstCall/ -- China Shenghuo Pharmaceutical Holdings, Inc. (Amex: KUN) ("China Shenghuo" or "the Company"), which is engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products in the People’s Republic of China ("PRC"), today announced it will conduct a conference call at 8:00 a.m. EDT on Wednesday, April 2, 2008, to discuss the Company’s financial results for the fiscal year ended December 31, 2007.
Hosting the call will be Mr. Feng Lan, President, and Ms. Qionghua Gao, Chief Financial Officer.
To participate in the event by telephone, please dial (800) 638-4930 five to 10 minutes prior to the start time (to allow time for registration) and reference the conference ID 28825392. International callers should dial (617) 614-3944 and reference the same passcode.
A digital replay of the call will be available on Wednesday, April 2 at approximately 10:00 a.m. EDT through Wednesday, April 9 at 12 p.m. EDT. To listen to the replay, dial (888) 286-8010 and enter the conference ID number 63812946. International callers should dial (617) 801-6888 and enter the same conference ID number.
The conference call will also be webcast live over the Internet and can be accessed by all interested parties at the company’s Web site: http://www.shenghuo.com.cn.
To monitor the live webcast, please visit the Company’s Web site and click on the webcast link at least 15 minutes prior to the start of the call to register, download, and install any necessary audio software. An audio replay of the event will be archived on China Shenghuo’s Web site.
About China Shenghuo Pharmaceutical Holdings, Inc.
Founded in 1995, China Shenghuo Pharmaceutical Holdings, Inc. ("China Shenghuo" or "the "Company") is a specialty pharmaceutical company that focuses on the research, development, production and marketing of Sanchi-based medicinal products. Through its subsidiary, Kunming Shenghuo Pharmaceutical (Group) Co., Ltd. ("Kunming Shenghuo"), it owns thirty-one SFDA (State Food and Drug Association)-approved medicines, including the flagship product Xuesaitong Soft Capsules, which has already been listed in the Insurance Catalogue. At present, China Shenghuo incorporates a sales network of agencies and representatives throughout China, which markets Sanchi-based traditional Chinese medicine to hospitals and drug stores as prescription and OTC drugs primarily for the treatment of cardiovascular, cerebrovascular and peptic ulcer disease. The Company also exports medicinal products to Asian countries such as Indonesia, Russia and Kyrgyzstan. For more information, please visit http://www.shenghuo.com.cn
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: This press release contains certain "forward-looking statements," as defined in the United States Private Securities Litigation Reform Act of 1995, that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management’s current expectations. Such factors include, but are not limited to, the company’s reliance on one supplier for Sanchi, ability to develop and market new products, ability to establish and maintain a strong brand, continued maintenance of certificates, permits and licenses required to conduct business in China, protection of company’s intellectual property rights, market acceptance of the company’s products, changes in the laws of the People’s Republic of China that affect the company’s operations, the company’s ability to obtain all necessary government certifications and/or licenses to open and operate retail specialty counters to offer its cosmetic products and conduct the company’s business, cost of complying with current and future governmental regulations and the impact of any changes in the regulations on the company’s operations and other factors detailed from time to time in the Company’s filings with the United States Securities and Exchange Commission and other regulatory authorities. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
For more information, please contact:
China Shenghuo Pharmaceutical Holdings, Inc
Ms. Gao Qionghua, CFO
Tel: +86-871-7282608
Email: qionghua_kmsh@163.com
CCG Elite Investor Relations
Crocker Coulson, President
Tel: +1-646-213-1915 (New York)
Email: crocker.coulson@ccgir.com
